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Background: Aptamer-based tumor targeted drug delivery system is a promising approach that may increase the
efficacy of chemotherapy and reduce the related toxicity. HER2 protein is an attractive target for tumor-specific
drug delivery because of its overexpression in multiple malignancies, including breast, gastric, ovarian, and lung
cancers.
Methods: In this paper, we developed a new HER2 aptamer (HB5) by using systematic evolution of ligands by
exponential enrichment technology (SELEX) and exploited its role as a targeting ligand for delivering doxorubicin
(Dox) to breast cancer cells in vitro.
Results: The selected aptamer was an 86-nucleotide DNA molecule that bound to an epitope peptide of HER2 with
a Kd of 18.9 nM. The aptamer also bound to the extracellular domain (ECD) of HER2 protein with a Kd of 316 nM,
and had minimal cross reactivity to albumin or trypsin. In addition, the aptamer was found to preferentially bind
to HER2-positive but not HER2-negative breast cancer cells. An aptamer-doxorubicin complex (Apt-Dox) was
formulated by intercalating Dox into the DNA structure of HB5. The Apt-Dox complex could selectively deliver
Dox to HER2-positive breast cancer cells while reducing the drug intake by HER2-negative cells in vitro. Moreover,
Apt-Dox retained the cytotoxicity of Dox against HER2-positive breast cancer cells, but reduced the cytotoxicity to
HER2-negative cells.
Conclusions: The results suggest that the selected HER2 aptamer may have application potentials in targeted
therapy against HER2-positive breast cancer cells.
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Breast cancer is the most common malignancy among
women worldwide. The overexpression of HER2 (human
epithelial growth factor receptor 2) is found in approxi-
mately 20-30% of breast cancer [1]. HER2-positive breast
cancer is associated with more malignant behaviors, in-
cluding increased invasiveness, higher recurrence, and
reduced overall survival [2-4], comparing to other types
of breast cancer. Moreover, more than half of the HER2-
positive women are ER/PR-negative, suggesting that a
fair proportion of HER2-positive breast cancers do not* Correspondence: yangxianda2009@yahoo.cn
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reproduction in any medium, provided the orrespond well to endocrine therapies [5,6]. For those
patients only accepting the conventional treatments of
surgical resection followed by chemo- and endocrine
therapies, the median survival time of HER2-positive
patients was about half of that of HER2-negative cases
[7]. In view of the above situation, the development of
novel therapy for HER2-positive breast cancer, such as
tumor-targeted therapy, is an inevitable trend. Targeted
therapy is characterized by selective killing of tumor
cells with minimal influence to normal cells, and may
improve therapeutic efficacy and reduce adverse effect.
Trastuzumab (Herceptin), a humanized HER2 monoclo-
nal antibody, has been approved as a first line targeted
treatment of HER2-positive metastatic breast cancer.
However, drug resistance is developed rapidly withThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Therefore, it is necessary to develop novel targeting
therapeutic strategies for treatment of HER2-positive
breast cancer.
Tumor-targeted therapy requires ligands that can bind
to cancer cells. In addition to antibodies, other types of
novel tumor-targeting ligands have emerged in the past
decades [12]. One new class of ligands are aptamers,
which are single-stranded oligonucleotides that may
serve as targeting molecules in therapeutic and diagnos-
tic applications [12]. Aptamers have certain advantages
as ligands, such as high affinity, excellent specificity, and
low immunogenicity. Aptamers are also easy to
synthesize and modify chemically [13]. Based on these
advantages, aptamers have broad prospect in therapeutic
applications. The first aptamer drug, Mucagen, was
approved for clinical use years ago. Other aptamer-based
agents are being actively tested in clinical trials [14,15].
Moreover, aptamers could also be employed as tumor-
targeting ligands to significantly enhance the treatment
outcome in animal tumor models [16-19]. A specially
designed aptamer–siRNA chimera that significantly
enhanced the inhibition of prostate cancer in mice when
administered systemically [19]. It was also reported that
aptamer-conjugated to docetaxel-containing nanoparti-
cles could increase the cancer-specific cytotoxicity both
in vitro and in vivo [18]. These studies suggest that apta-
mers can serve as excellent tumor-targeting ligands in
targeted therapeutic systems.
So far, however, no aptamer has been explored as
tumor-targeting ligand for delivering chemotherapeutic
agent to HER2-positive breast cancer, and there are lim-
ited published studies on HER2 aptamers [20,21]. In the
present study, we developed a new DNA aptamer (HB5),
which was found capable of binding to both the HER2
protein and the HER2-positive breast cancer cells. To
evaluate whether the aptamer could be employed to se-
lectively carry cytotoxic drug to HER2-positive breast
cancer cells, we also constructed an aptamer-doxirubicin
complex (Apt-Dox). We now report that Apt-Dox can
selectively deliver doxorubicin to HER2-positive breast
cancer cells in vitro.Methods
Cell lines and cultures
The Cell lines, SK-BR-3 (human breast cancer), MDA-
MB-231 (human breast cancer), MCF-7 (human breast
adenocarcinoma) were obtained from the Cell Re-
source Center of Chinese Academy of Medical Sciences
(Beijing, China). All cell lines were incubated in
DMEM medium supplemented with 100 U/mL penicil-
lin, 100 μg/mL streptomycin and 10% fetal bovine
serum (Gibico) in 5% CO2 and humid atmosphere at37°C. All experiments were performed on cells in the
exponential growth phase.Random DNA library and primers
A starting ssDNA library consisted of 86 nucleotides,
containing a 40-base random region flanked by two
fixed sequences for the amplification reaction. The
library sequence was 5’-AACCGCCCAAATCCCTAA
GAGTC-N40-CACAGACACACTACACACGCACA-3’.
A FITC- labeled 5’ Primer P1 (5’-FITC-AACCGCCCA
AATCCCTAAGAGTC-3’) was used in the PCR to
monitor the binding of aptamer with target agents dur-
ing the selection process. A biotinylated 3’ primer P2
(5’-biotin-TGTGCGTGTGTAGTGTGTCTGTG-3’) was
used to amplify double strand DNA (dsDNA) and en-
able this double labeled dsDNA binding to streptavidin-
coated magnetic beads. The FITC-conjugated sense
single-strand DNA (ssDNA) was separated from the
biotin- and FITC- labeled dsDNA by denaturing in alkaline
condition (0.1 M NaOH) and applying a magnetic field.
The FITC-labeled ssDNA were used for aptamer selection.
Unlabeled P1 and P2 primers were used for cloning the
enriched library after the end of selection. All primers and
the initial random DNA library were synthesized and puri-
fied by Invitrogen China. Streptavidin-coated magnetic
beads were purchased from Promega (USA).Targets immobilization
HER2 Peptide of at least 95% purity was synthesized by
SBS Genetech (Beijing, China). Magnetic monodispersed
microspheres embedded in SiO2 (Affimag SLE, 3 μm-
4 μm) were purchased from BaseLine ChromTech
(Tianjin, China). 1-Ethyl-3-(3-dimethyllaminopropyl)
carbodiimide hydrochloride (EDC) was purchased from
Sigma. Bovine serum albumin (BSA) and trypsin were
purchased from Amresco Inc. (USA). The extracellular
domain of HER2 protein (HER2 ECD) was purchased
from Sino Biological Inc. (Beijing, China).
A peptide from the juxtamembrane region of HER2
ECD was used as the target for selection, with the se-
quence of INCTHSCVDLDDKGCPAEQR. The HER2
peptide was immobilized to carboxylated magnetic beads
through cross-linking of –COOH and –NH2. The car-
boxylated SLE beads (1x105, 200 μL) were washed twice
with 200 μL of PBS. The beads were resuspended in
200 μL deionized water dissolving with HER2 peptide
(2 μg) and EDC (40 mM), and then incubated at room
temperature with gentle stirring for 2 h. The beads were
then washed for three times with PBS, and stored at 4°C
in PBS. The same method was utilized to conjugate the
beads with other substances, including HER2 ECD pro-
tein, bovine serum albumin (BSA), trypsin and HER2
ECD, for specificity assays of the selected aptamer.
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To reduce background interference, 0.1 mg/mL salmon
sperm DNA and 1 mg/mL of BSA were added to the
binding buffer (Hanks buffer). The procedures of selec-
tion were as follows: in the initial selection round, the
ssDNA pool (200 pmol) was first heated at 95°C for
5 min and then cooled immediately on ice for 15 min.
The HER2-peptide coated beads were suspended in 200
μL of binding buffer containing 200 pmol of random
ssDNA. After incubating the mixture at 37°C for 30 min
with gentle shaking, the unbound oligonucleotides were
removed by washing four times with 500 μL of binding
buffer. Subsequently, target-binding oligonucleotides on
beads were amplified by PCR with FITC- or biotin-
labeled primers (25 cycles of 40 s at 94°C, 30 s at 65°C,
40 s at 72°C, followed by 10 min at 72°C, the Taq poly-
merase and dNTPs were obtained from Takara). The
selected sense ssDNA were separated from the biotiny-
lated antisense ssDNA strand by streptavidin-coated
magnetic beads and used for the next round of SELEX.
After multiple rounds of selection, the selected ssDNA
pool was PCR-amplified using unmodified primers and
cloned into Escherichia coli with the TA cloning kit for
DNA sequencing.
Flow cytometric analysis
To monitor the enrichment of aptamer pool each round,
the FITC-labeled ssDNA pool were incubated with
HER2-peptide coated magnetic beads in 200 μL of selec-
tion buffer containing 10% FBS at 37°C for 30 min. The
beads were washed twice with 0.5 mL of binding buffer,
suspended in 0.2 ml of binding buffer, and then analyzed
by Flow cytometry (AccuriW C6 Flow Cytometer, BD).
Peptide-coated beads stained with FITC-labeled random
ssDNA were used as control.
To evaluate the binding specificity of the aptamers,
FITC-labeled aptamers were separately incubated with
HER2 ECD, BSA, or trypsin-coated magnetic beads. The
beads were washed twice with 0.5 mL of binding buffer,
suspended in 0.2 mL of binding buffer, and analyzed by
Flow Cytometry. For assessing aptamer binding on cells,
the cells were scraped off the culture bottle and washed
twice with Hanks buffer. The FITC-labeled aptamers
were incubated separately with 5 × 105 of SK-BR-3,
MDA-MB-231, or MCF-7 in binding buffer at 37°C for
30 min. Cells were then washed twice with Hanks buffer
and analyzed by flow cytometry.
To evaluate the binding affinity of the aptamer to
HER2 structure, we incubated HER2-peptide coated
magnetic beads with varying concentrations of the
FITC-labeled aptamer HB5 in 200 μL binding buffer at
37°C for 30 min. The beads were washed twice with
0.5 mL of binding buffer, suspended in 0.2 mL of bind-
ing buffer, and then analyzed by Flow Cytometry. Thepeptide-coated beads stained with FITC-labeled random
ssDNA were used as a control. All of the experiments
for binding assay were repeated for at least three times.
The mean fluorescence intensity of the aptamer bound
to the target was used to calculate the specific binding
by subtracting the mean fluorescence intensity of non-
specific binding from unselected library DNA. The equi-
librium dissociation constant (Kd) of the aptamer was
obtained by fitting the dependence of fluorescence inten-
sity of specific binding on the concentration of the apta-
mers to the equation: Y =B max X/ ( Kd +X) [22].
Apt-Dox complex
The aptamer were first heated at 95°C for 5 min and
then cooled immediately on ice for 15 min. Next, a fixed
concentration of Dox (3 nM) was incubated for 1 h with
various concentrations of aptamer HB5, at aptamer/Dox
molar ratios of 1, 0.1, 0.01, 0.003, 0.0001, and 0, respect-
ively. The fluorescence spectrum of doxorubicin was
examined in 96-well black plate by a Synergy4 analyzer
(λEx = 488 nm, λEm = 520–720 nm).
Cellular uptake studies
The cellular uptake of Apt-Dox or free Dox by cells was
studied by confocal microscopy (Perkin Elmer Ultraview,
US) and flow cytometry. Cells were allowed to adhere to
a glass cover slip for 24 h. The cells were then incubated
with 1.5 μM of Dox or Apt-Dox complex for 2 h at 37°C.
After washing twice with Hanks buffer, the cells were
fixed with 4% formaldehyde for 10 min and analyzed by
confocal fluorescence scanning microscopy.
For flow cytometry analysis, cells were scraped off
from the culture bottle and washed twice with Hanks
buffer. The cells were incubated with 1.5 μM Dox or
Apt-Dox complex for 4 h at 37°C, and washed twice
with Hanks buffer. The cells were then fixed with 4% for-
maldehyde for 10 min and analyzed by Flow Cytometry.
In vitro cytotoxicity assays
To evaluate the cytotoxicity of Apt-Dox or Dox against
SK-BR-3 and MDA-MB-231 cells, both cell lines were
first grown in 96-well plates, and then co-incubated with
Apt-Dox, Dox, or aptamer separately at the concentra-
tion of 2 μM for 4 h at 37°C. The cells were washed with
Hanks buffer twice, and cultured for a further 40 h.
Afterwards, MTS viability assay was performed accord-
ing to the standard protocol outlined by the manufac-
ture (Promega, US).
Statistics
Statistical analysis was performed with the statistical
SPSS 13.0 software. The nonparametric test was used
to calculate the probability of significant differences
Figure 2 Flow cytometric evaluations of aptamer HB5’s binding
property. Beads coated with HER2 peptide (blue lines), HER2 ECD
protein (red lines), BSA (black lines), or trypsin (yellow lines) were
incubated separately with either FITC-labeled aptamer (A) or
FITC-labeled random DNA (B), and analyzed by flow cytometry.
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In this study, the HER2 aptamers were developed using a
standard SELEX technique and a HER2 epitope peptide
as the target. The peptide was conjugated covalently to
SLE beads via EDC-mediated reaction. To monitor the
enrichment of HER2 aptamers during each round of se-
lection, the handled beads were incubated with FITC-
labeled ssDNA pool for flow cytometry assay. Compared
with the initial random DNA library, increasing fluores-
cent intensities were observed, suggesting that more
ssDNA bound to the peptide-coated beads with each
round of selection (Figure 1A). The enriched HER2 apta-
mers were subsequently cloned, and 96 clones were ana-
lyzed for further characterization. Among these clones,
one aptamer termed HB5 showed relatively high binding
capacity to the target HER2 peptide. The primary se-
quence of the aptamer HB5 is 5’-AACCGCCCAAAT
CCCTAAGAGTCTGCACTTGTCATTTTGTATATGTA
TTTGGTTTTTGGCTCTCACAGACACACTACACAC
GCACA-3’. The predicted secondary structure of HB5
was shown in Figure 1B.
Binding property of the aptamer HB5
The aptamer HB5 was selected to bind the target HER2
peptide. It is important for the aptamer to also recognize
the extracellular domain (ECD) of HER2 protein, which
is the exposed HER2 structure on tumor cells. We there-
fore evaluated the binding of the atpamer to the HER2
ECD. The HER2 ECD protein was covalently conjugated
to magnetic beads, incubated with FITC-labeled HB5,
and analyzed by flow cytometry. FITC-labeled initial
random DNA library was used as control. As shown in
Figure 2 (red lines), the fluorescent signal of HB5
increased significantly over the control. The dataFigure 1 Aptamer selection. (A) Flow cytometry profiles monitoring the
starting random DNA pool (solid histogram), 1st round (black line), 3rd roun
structure of the aptamer HB5.indicated that, in addition to binding the target HER2-
peptide, the aptamer HB5 could also bind to the HER2
ECD protein.
To evaluate whether the aptamer HB5 had a relatively
preferred binding to the HER2 structure, we directly
compared, under the same experimental conditions, the
bindings of the aptamer to HER2 peptide, HER2 ECDaptamer enrichment during the selection process. From left to right,
d (grey line), and 5th round (silver line). (B) The predicted secondary
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because it is the most abundant protein in blood; and
trypsin was commonly used for testing the binding speci-
ficity of the aptamers. The results are presented in Figure
2. While aptamer HB5 showed relatively strong bindings
to HER2 peptide and HER2 ECD protein, its binding to
BSA or trypsin was weak (Figure 2 A). In addition, ran-
dom DNA showed no binding preference to all four struc-
tures (Figure2 B). The data suggested that the aptamer
HB5 had a targeting preference towards HER2, and
tended not to bind the other proteins such as BSA or
trypsin.
To quantitatively evaluate the HER2 binding affinity of
the aptamer HB5, HER2 peptide-coated beads were
incubated with increasing concentrations of FITC-
labeled HB5 and analyzed by flow cytometry. Using a
non-linear regression analysis, the Kd of the aptamer for
binding with the HER2 peptide was estimated to be 18.9
nM (Figure 3A). It is also important to quantify theFigure 3 Quantitative assay of HB5’s binding affinity. Beads
coated with HER2 peptide (A) or HER2 ECD protein (B) were
incubated with varying concentrations of FITC-labeled aptamers.
The mean fluorescence intensity of the unselected DNA library
(background binding) at each concentration was subtracted from
the mean fluorescence intensity of the corresponding aptamer.
The actual fluorescence intensity was fitted into Sigmaplot to
determine the apparent Kd.affinity of the aptamer for recognizing the extracellular
domain (ECD) of HER2 protein, which is the exposed
HER2 structure on tumor cells. Similar experiments were
conducted using beads coated with HER2 ECD protein,
and the Kd of the aptamer for binding with the HER2
ECD was estimated to be 316 nM (Figure 3B).Aptamer HB5 selectively recognized HER2-positive breast
cancer cells
Although the aptamer HB5 demonstrated good binding
profiles for the HER2 peptide and the HER2 ECD pro-
tein, it is still unknown whether the aptamer would bind
to the HER2-positive breast cancer cells. To address this
issue, we directly compared the bindings of the aptamer
to either the HER2-positive (SK-BR-3), or the HER2-
negative breast cancer cells (MDA-MB-231 and MCF-7)
[23] under the same experimental conditions. The HER2
expressions in these breast cancer cell lines had been ex-
tensively analyzed by prior studies with mRNA or West-
ern assays [24-27]. FITC-labeled HB5 was incubated
with the cells, which were later analyzed by flow cytome-
try. The cells incubated with FITC-labeled random DNA
were used as the control. As presented in Figure 4, while
aptamer HB5 showed relative strong binding to HER2-
positive breast cancer cells (SK-BR-3), the bindings to
HER2-negative cells (MDA-MB-231 and MCF-7) were
weak (Figure 4A). In addition, random DNA showed no
binding preference to all the cell lines (Figure 4B). The
results indicated that the aptamer HB5 could preferen-
tially bind to HER2-positive breast cancer cells, possibly
by recognizing the HER2 structure on the surface of
these cells.Formation of aptamer-doxorubicin complex
To explore whether the aptamer HB5 could be
employed to selectively carry cytotoxic agents to HER2-
positive breast cancercells, we next constructed an
aptamer-doxorubicin complex (Apt-Dox), utilizing the
fact that doxorubicin tended to intercalate into DNA
structures. The first question here was whether Dox in-
deed intercalated into the DNA structure of the aptamer
HB5. It is well known that Dox emits a fluorescence that
will be quenched after intercalation into DNA structure
[28]. This feature was used in this study to evaluate the
formation of the Apt-Dox complex. Specifically, a fixed
concentration of Dox was mixed with HB5 aptamers of
increasing molar ratios. The mixtures were later ana-
lyzed by fluorescence spectroscopy. As shown in Figure 5,
the native fluorescence spectrum of Dox decreased with
increasing concentrations of the aptamer. The fluores-
cence of Dox was almost completely quenched when the
Apt/Dox molar ratio gradually increased to 0.1. The
results suggested that most Dox intercalated into the
Figure 4 Flow cytometric profiles of HB5’s bindings to
HER2-positive (SKBR3) or HER2-negative (MDA-MB-231 and
MCF7) breast cancer cells. SKBR3 (blue lines), MDA-MB-231
(red lines), or MCF7 (black lines) cells were incubated separately with
either FITC-labeled aptamer (A) or FITC-labeled random DNA (B),
and analyzed by flow cytometry.
Figure 5 Fluorescence spectra assay of Apt-Dox. Doxorubicin
solution mixed with increasing molar ratios of the HB5 aptamer
(from top to bottom: 0, 0.0001, 0.003, 0.03, 0.1, and 1).
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ratio increased to 0.1 or above.
The Apt-Dox complex was selectively uptaken into
HER2-positive breast cancer cells
To evaluate the feasibility of the Apt-Dox complex as a
tumor-targeted drug delivery system, we performed
in vitro drug uptake studies with both HER2-positive
and -negative breast cancer cells. The HER2-positive
breast cancer cells used here were SK-BR-3 cells, which
abundantly express HER2 protein on their plasma mem-
brane [1,26]. The HER2-negative cells were the MDA-
MB-231 cells, which do not express any detectable level
of HER2 protein [29,30]. Confocal microscopy was
employed to evaluate the fluorescence emitted by Dox
and the uptake of the drug by the two types of cells.
While free Dox was taken up by both cell lines
(Figure 6A&B), the Apt-Dox was mainly uptaken by
HER2-positive cells (Figure 6C). The results suggested
that Apt-Dox could discriminate efficiently betweenFigure 6 Evaluation of cellular uptake of Dox. Confocal
microscopy images of HER2-positive SK-BR-3 cells and HER2-negative
MDA-MB-231 cells treated with free Dox (A&B) or Apt-Dox (C&D).
Flow cytometry profiles of HER2-positive SK-BR-3 cells (E) and
HER2-negative MDA-MB-231 cells (F) after treatments with free Dox
(black lines) or Apt-Dox (grey lines). The filled histograms are the
control signals generated by untreated cells.
Figure 7 Cytotoxicity assays of Dox and Apt-Dox. The
HER2-positive SK-BR-3 cells and the HER2-negative MDA-MB-231
cells were treated with aptamer, Dox, or Apt-Dox. After 40 h of
further incubation, the cells were evaluated with standard MTS assay
(mean± SD, n = 6). The star indicates a statistically significant
difference between the Dox and the Apt-Dox groups (p< 0.05).
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HB5 possibly retained HER2-binding ability while carry-
ing the Dox within its DNA structure. It should be
noted that the Apt-Dox produced very weak staining in
MDA-MB-231 cells (Figure 6D), a result consistent
with the lack of HER2 expression in these cells. Overall,
the data indicated that the Apt-Dox conjugate could
selectively enter HER2-positive breast cancer cells, while
free Dox could not differentiate between HER2-positive
and -negative cells. Interestingly, in HER2-positive SK-
BR-3 breast cancer cells, the Apt-Dox stained both the
nuclei and the cytoplasm (Figure 6C), while the free Dox
exclusively stained the cell nuclei (Figure 6A). This sug-
gested that the uptake mechanisms of the free DOX and
the Apt-Dox complex might be different.
Next we performed flow cytometry experiments to
further evaluate the uptake of Apt-Dox and free Dox by
HER2-positive and -negative breast cancer cells
(Figure 6E&F). For HER2-positive SK-BR-3 cells, the
fluorescent signals from free Dox or Apt-Dox were
similar (Figure 6E); whereas for HER2-negative MDA-
MB-231 cells, the fluorescent signal from Apt-Dox was
lower than that from free Dox (Figure 6F). Taken to-
gether, both the confocal and flow cytometry studies
suggested that Apt-Dox conjugate mainly entered
HER2-positive breast cancer cells, while free Dox
entered both HER2-positive and -negative cells.
The Apt-Dox complex selectively reduced cytotoxity to
HER2-negative breast cancer cells
To examine whether the selective delivery of Apt-Dox to
HER2-positive breast cancer cells would result in targeted
cytotoxicity, we compared the cytotoxic efficacies of free
Dox and Apt-Dox on HER2-positive and -negative cells
in vitro with MTS assay. The data showed that while free
Dox produced similar cytotoxicity against HER2-positive
and -negative breast cancer cells, Apt-Dox generated a
moderately reduced cytotoxicity against the HER2-
negative cells (Figure 7, p< 0.05). The aptamer itself had
no inherent cytotoxicity to HER2-positive or -negative
cells. Our data suggested that the HER2 aptamer could
selectively deliver Dox to HER2-positive breast cancer
cells and might potentially reduce the adverse effects of
the drug to HER2-negative cells.
Discussion
HER2 over-expression is found not only in 20–30% of
breast cancers, but also in gastric, ovarian, bladder, and
lung cancers [22,31-36]. Therefore, HER2 may serve as a
potential target for targeted tumor therapy against many
malignancies. Aptamers can bind to target with high af-
finity and specificity, and may be employed as targeting
ligand in selective drug delivery system. Here in this
study, using the SELEX technique with a HER2 peptideas the target, we developed a novel HER2 aptamer
(HB5) with a Kd of 18.9 nM for binding with the target
peptide (Figure 1 & 3A). In addition to binding the
HER2 peptide, HB5 could also bind to HER2 ECD pro-
tein with a Kd of 316 nM (Figure 2 & 3B), and with min-
imal cross-reactivity to trypsin and albumin (Figure 2),
suggesting that the aptamer had a binding preference for
HER2 structures. Moreover, the aptamer HB5 could se-
lectively bind to HER2-positive breast cancer cells with
weak cross-reaction to HER2-negative cells (Figure 4).
An aptamer-doxorubicin complex (Apt-Dox) was
formed by intercalating Dox into the DNA structure of
the aptamer (Figure 5). While retaining the efficacy of
doxorubicin against HER2-positive breast cancer cells,
the Apt-Dox complex reduced the drug intake and the
toxicity to HER2-negative cells (FigureS 6&7). The
results suggested that Apt-Dox could discern target and
non-target cells, and that HER2 aptamer might serve as
targeting ligand for selective drug delivery to HER2-
positive breast cancer cells.
Monoclonal antibodies have been the main approach
for HER2-targeted cancer therapy, and trastuzumab
(Herceptin), a humanized HER2 monoclonal antibody,
has been approved for treatment of HER2-positive breast
cancer. However, drug resistance is commonly and rap-
idly developed with trastuzumab treatment [2,3,8-11],
making it necessary to explore other HER2-targeting
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some RNA or DNA HER2 aptamers [20,21]. Kim et al.
developed an RNA aptamer using HER2 protein as the
target, and proposed that the selected aptamer could po-
tentially be utilized in constructing novel imaging agents
for HER2-positive cancers [20]. Kazem et al. also
obtained a library of DNA aptamers by using HER2-
positive cells as the target for aptamer selection [21]. So
far, however, HER2 aptamer has not been explored as
the tumor-targeting ligand for selective drug delivery to
HER2-positive breast cancer cells. To investigate
whether HER2 aptamer can be utilized in targeted HER2
therapy, we developed an aptamer-based doxorubicin
delivery system in this study, and found that the aptamer
could be employed to selectively deliver cytotoxic agent
to HER2-postive breast cancer cells in vitro. The results
suggest that, in addition to monoclonal antibodies,
HER2 aptamers may also have application potentials in
construction of novel HER2-targeted therapeutic
systems.
There are multiple technical approaches to develop
HER2 aptamers. One of them is termed Cell-SELEX,
which uses the entire HER2-positive cell as the target
during the aptamer selection process [37]. One potential
drawback of this approach is that the selected aptamers
may or may not bind to the HER2 structure, since these
aptamers also may bind to the other proteins in the cell
membrane of the target cell [30]. In order to select out
aptamers that could truly bind to HER2 structure, here
in this study, we chose an epitope sequence (peptide) of
HER2 protein as the target in our SELEX process. The
peptide sequence was a part of the extra-cellular domain
(ECD) of HER2 protein, and contained 20 AAs. The ad-
vantage of this target peptide was that it could be
synthesized with high purity, allowing us to select a
population of aptamers that mostly bound to the target.
Interestingly, some of the aptamers thus generated could
also bind to the ECD of HER2 protein and the HER2-
positive breast cancer cells (Figure 2&4). We postulated
that this might be related to the properties of the pep-
tide and the structure of the HER2 protein. First, the
peptide is a confirmed B cell epitope that is found close
to the cell membrane of the ECD of HER2 protein [38].
B cell epitope usually locates at a flexible and exposed
part of the protein [30,39]. Second, HER2 crystal struc-
ture reveals that the extra-cellular domain of this protein
is always in an extended conformation [40-43]. Thus,
the target epitope is probably exposed on the surface of
the HER2 protein, and the aptamer recognizing this epi-
tope may consequently bind to the HER2 protein and
the HER2-positive cells as well. It is interesting that the
Kd for binding with the HER2 ECD protein was higher
than that for binding with the HER2 peptide. One factor
possibly contributing to the difference is that the originalaptamer binding site on the HER2 peptide might be par-
tially masked by the more complex structure of the HER2
ECD protein. It is also possible that the binding affinity
of the aptamer might be weakened by the influences from
the protein structures adjacent to the aptamer binding
site.
The binding preference of an aptamer is important for
its application as a targeting ligand. An ideal tumor-
targeting aptamer should bind to the target molecule (in
this case, the HER2 structure), with minimal binding to
other proteins. Since albumin is the most abundant pro-
tein in blood, we added BSA to the selection solution as
a background component, in order to reduce the apta-
mer’s binding to albumin. As a result, the HER2 aptamer
HB5 developed here had a weak binding to BSA, while
maintaining a good binding profile to HER2 structures.
Interestingly, the HER2 aptamer also had minimal re-
activity to trypsin (Figure 2), which was commonly used
for testing the binding specificity of the aptamers. More-
over, the HER2-aptamer exhibited a relatively strong
binding to HER2-positive breast cancer cells, but min-
imal binding towards the HER2-negative cells (Figure 4).
These results indicated that the HER2 aptamer HB5
exhibited certain degrees of targeting preference in vitro.
Nevertheless, the aptamer’s in vivo HER2 preference still
needs to be verified with future animal experiments in
the follow-up studies.
Prior studies have shown that aptamers can deliver
doxorubicin to tumor cells that bind the aptamer [28].
Similarly, in this study, the confocal microscopy demon-
strated that the Apt-Dox selectively delivered doxorubi-
cin to HER2-positive breast cancer cells (Figure 6C).
Interestingly, in HER2-positive breast cancer cells, Apt-
Dox stained both the nuclei and the cytoplasm, while
the free Dox exclusively stained the nuclei. This observa-
tion may reflect a difference in the drug uptake mechan-
isms between Apt-Dox and the free Dox. We
hypothesized that the lipophilic free Dox entered cells
via passive diffusion, while the hydrophilic aptamer pre-
vented the Apt-Dox from freely defusing into the lipid
cell membrane. The Apt-Dox possibly entered HER2-
positive cells via a receptor-mediated endocytosis. In
other words, the aptamer in the Apt-Dox recognized
and bound to the HER2 structure on HER2-positive
cells. Since the binding site was very close to the cell
membrane, the binding might induce a conformational
change of HER2 protein and disturb the adjacent cell
membrane, resulting in the endocytosis of the Apt-Dox
complex. Obviously, extensive future research is needed
to clearly unveil the mechanism by which the Apt-Dox
entered the HER2-positive cancer cells. It should be
noted that the Apt-Dox produced weak staining in the
HER2-negatives cells, a finding consistent with the lack
of HER2 expression in these cells (Figure 6D). The
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selectively deliver doxorubicin to HER2-positive breast
cancer cells. This presumably would decrease the ad-
verse effects of Dox against non-tumor tissues with low
HER2 expression. Future research may concentrate on
improving the binding kinetics, targeting efficacy, drug-
loading capacity, and the in vivo stability of the targeted
drug delivery system based on HER2 aptamers. In
addition, extensive animal studies are also needed to
evaluate the pharmacokinetics and the in vivo efficacy of
the HER2-targeted drug-delivery system.
Conclusions
In this study, a newly developed DNA aptamer (HB5)
was found capable of binding to HER2 protein and
HER2-positive breast cancer cells, with minimal binding
to HER2-negative cells. A complex of the aptamer and
doxorubicin (Apt-Dox) could selectively deliver doxo-
rubicin to HER2-positive breast cancer cells while redu-
cing the drug intake by HER2-negative cells. The results
suggest that HER2 aptamers may have application
potentials in targeted therapy against HER2-positive
breast cancer cells.
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